{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-22-000091","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.139685+00:00","generated_at":"2026-06-24T07:48:48.646401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Pfizer Q2 revenue $27.7B record; adj. EPS $2.04 (+92%); raises FY guidance $0.24","bullets":["Q2 revenue $27.7B (+47% YoY, +53% operational); Paxlovid contributed $8.1B, Comirnaty +20% operationally.","Reported diluted EPS $1.73 (+77%); adjusted diluted EPS $2.04 (+92%), beating expectations.","Raised FY2022 adj. EPS guidance to $6.30-6.45 (lower end up $0.05); revenue reaffirmed $98-102B.","H1 capital: $4.5B dividends, $2B share buybacks; completed $6.3B Arena acquisition; announced $13.3B Biohaven deal."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-22-000091","json":"https://secwatch.observer/filing/0000078003-22-000091.json","markdown":"https://secwatch.observer/filing/0000078003-22-000091.md","text":"https://secwatch.observer/filing/0000078003-22-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/0000078003-22-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/pfe-20220728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:48:48.646401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}